RNAi-based Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Meta-analysis of Randomized Clinical Trials
Oguz Kagan Sahin1, Luana Makita2, Paweł Łajczak3, Aishwarya Koppanatham4, Murilo Cruccioli5, Letícia Rocha Campos6, Yasmin Silva7, Pedro Henrique Teixeira Carneiro8
1Acibadem University, 2Federal University of Parana, 3Medical University of Silesia, 4Andhra Medical College, 5Universidade Evangélica de Goiás, 6University of Ribeirão Preto, 7University of Debrecen, 8Universidade de Santo Amaro
Objective:

This meta-analysis aims to evaluate the efficacy and safety of RNA inhibitor therapies in treating Hereditary transthyretin amyloidosis (hATTR) with polyneuropathy.


Background:

hATTR is a genetic disorder characterized by the misfolding and deposition of transthyretin (TTR) protein in various tissues. RNA interference (RNAi) therapies offer a promising approach by selectively targeting and reducing mutant TTR protein levels. While these therapies have shown efficacy in treating hATTR with polyneuropathy, variations in response and safety profiles across different TTR mutations emphasize the need for personalized treatment and close monitoring.

Design/Methods:

PubMed, EMBASE, and Cochrane databases were searched for clinical trials that fit our inclusion criteria. We performed a meta-analysis using RStudio to pool data. Proportional outcomes were summarized as pooled proportions with 95% confidence intervals (CIs), using a random-effects model. Continuous outcomes were calculated by pooling mean values with 95% CIs. Heterogeneity was assessed using the I² statistic and Cochran’s Q test. Subgroup analysis is performed based on individual RNAi drugs.

Results:

We included 5 trials involving 595 patients received Patisiran, Eplontersen, Inotersen, or Vutisiran. The mean change from baseline in mNIS+7 was -0.63 (95% CI: -3.44; 2.18), with the Patisiran subgroup being more effective. The mean change from baseline in Norfolk QOL-DN score was  −1.89 (95% CI: -3.09; -0.68). Serum TTR reduction from baseline was -77.17% (95% CI: -80.56; -73.79). Serious treatment-emergent adverse events were reported in 29.67% of the patients (95% CI: 22.54; 36.80).

Conclusions:
Our results suggest that RNAi-based therapies are promising for hATTR with polyneuropathy treatment, showing improvements in neurological function, quality of life, and an acceptable safety profile. However, evidence is limited, with heterogeneity in long-term safety and effectiveness across studies. Further randomized trials are needed to clarify the role of RNAi therapeutics and optimize patient outcomes.
10.1212/WNL.0000000000211351
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.